Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

RoActemra®

Known as: RoActemra 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
ABSTRACT K-Ras mutations are a hallmark of human pancreatic adenocarcinoma (PDAC) and epithelial-mesenchymal-transition (EMT) is… Expand
2018
2018
TNFAIP3 encodes the NF-κB regulatory protein A20. High-penetrance heterozygous mutations in TNFAIP3 cause a haploinsufficiency of… Expand
Review
2017
Review
2017
Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra®), an IL-6 receptor antagonist, are approved (± methotrexate) in… Expand
  • table 1
  • table 2
  • table 3
2017
2017
Interleukin-6 (IL-6) is a proinflammatory cytokine produced by various cells. Emerging evidence shows that IL-6 plays critical… Expand
  • table 1
2017
2017
BackgroundRheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and anti-carbamylated protein (anti-CarP… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
2013
2013
Objectives To assess tolerance and safety of rheumatoid arthritis (RA) treatment by tocilizumab (TCZ) in real life Methods The… Expand
Highly Cited
2012
Highly Cited
2012
To the Editor: Anti-interleukin 6 receptor (anti-IL-6R) antibodies have been effective in experimental models of autoimmune… Expand
Review
2011
Review
2011
  • R. Alten
  • Therapeutic advances in musculoskeletal disease
  • 2011
  • Corpus ID: 8591212
Tocilizumab (TCZ; RoActemra® or Actemra®) is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6… Expand
  • table 1
  • table 2
  • figure 1
  • table 8
  • table 7
Review
2009
Review
2009
▼Tocilizumab (RoActemra – Roche) is a new biological agent available in the UK for the treatment of adults with rheumatoid… Expand